Cellular-level immune system – no defined molecular target

The term Cellular-level immune system – no defined molecular target refers to a classification used in pharmacological databases, such as ChEMBL, to describe therapeutic agents that act on the immune system through complex cellular mechanisms rather than by interacting with a single, well-defined molecular entity like a protein or receptor (ChEMBL, 2024). This category typically encompasses advanced therapies such as whole-cell vaccines, certain biological response modifiers, and adoptive cell therapies where the entire cell or a broad immune process is the functional unit of the treatment (National Cancer Institute, 2023). For example, Sipuleucel-T involves the activation of a patient's own dendritic cells to induce a T-cell response against prostate cancer, representing a systemic cellular intervention rather than a traditional small-molecule drug-target interaction (FDA, 2010). These therapies are primarily utilized in oncology and infectious diseases to enhance the body's natural defenses or to redirect immune activity against specific pathological cells (PubMed, 2022). Because these treatments involve multi-cellular pathways and systemic modulation, they often present unique clinical challenges, including the risk of severe immune-mediated adverse events like cytokine release syndrome (StatPearls, 2023).

Other names

Cell-based therapyNon-specific immunotherapyWhole-cell vaccineAdoptive cell transferBiological response modifier

Modulation of immune cell populations, recruitment, or systemic activity through cellular interactions rather than binding to a single, specific molecular target (e.g., receptor or enzyme).